Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 9

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 1
Chunk 9
---
clinical session. We are also collaborating with academic researchers to investigate EV characteristics in patients with Long COVID. These
exploratory programs are intended to inform potential future clinical indications and expand the utility of the Hemopurifier platform. 

     8 

Successful outcomes of
human trials will also be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier.
Some of our patents may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain
patent applications and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment
technology.

In addition to the foregoing, we are monitoring
closely the impact of inflation, recent bank failures and the war between Russia and Ukraine and the military conflicts in Israel and
the surrounding areas, as well as related political and economic responses and counter-responses by various global factors on our business.
Given the level of uncertainty regarding the duration and impact of these events on capital markets and the U.S. economy, we are unable
to assess the impact on our timelines and future access to capital. The full extent to which inflation, recent bank failures and the ongoing
military conflicts will impact our business, results of operations, financial condition, clinical trials and preclinical research will
depend on future developments, as well as the economic impact on national and international markets that are highly uncertain.

We incorporated in Nevada on March 10, 1999. Our
executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360.
Our website address is www.aethlonmedical.com.

Our common stock is listed on the Nasdaq Capital Market under the symbol
“AEMD.”

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

During the six months ended September 30, 2025,
there were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended
March 31, 2025.

REVERSE STOCK SPLITS

On October 16, 2025, the Company implemented a
1-for-10 reverse stock split of its then outstanding shares of common stock, with trading of the post-split shares beginning October 20,
2025. Accordingly, each 10 shares of outstanding common stock then held by our stockholders were combined